1. Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

3. NOACs in Stroke Prevention in AF

4. Defining Real-World Evidence

5. Uses of RWE

6. Appraising the Quality of RWE

7. Appraising the Quality of RWE (cont)

8. Appraising the Quality of RWE (cont)

9. XANTUS

10. XANTUS, XANTUS-EL, XANAP

11. XANTUS Rivaroxaban Treatment Profile

12. XANTUS Pooled Overall Safety Outcomes

13. XANTUS Risk Factors for Major Bleeding

14. XANTUS Modeled Effect of Modifiable Risk Factors

15. XANTUS Outcomes According to Dosing

16. XANTUS Inappropriate Dosing

17. Goals for Registry Data

18. Lessons From Registry Data: #1

19. Lessons From Registry Data: #2

20. Lessons From Registry Data: #3

21. NOACs in Frail Patients

22. NOACs in Frail Patients Results

23. Summary

24. Abbreviations

25. Abbreviations (cont)